This page shows what was measured, who it was measured in, and what that does not settle.
What Dexlansoprazole does in the body
Heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks
From the FDA-approved label: Dexlansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H + , K + )-ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, dexlansoprazole has been characterized as a gastric proton-pump inhibitor, in that it blocks the final step of acid production.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
RNAWiki has not recorded a supervision or regulatory status for this substance.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · UYE4T5I70X · read 2026-08-29
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 95 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Formulation
A formulation is the exact made-up form a substance comes in.
A picture of it, and where the picture fails
It is like the difference between a whole bean and instant coffee.
Where that stops being true. Coffee tastes different. A formulation can change how much reaches the blood.
What people get wrong. Two products with the same name are assumed to behave the same. They often do not.
The specific composition and physical form of a product, including salt, excipients and release profile.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
The rate of hospitalisation due to peptic ulcer bleeding in patients who enter the randomised study (only the first event per patient will be analysed), adjudicated by a blinded Committee as definite or probable.
✗ The study did not show it
Who was studied
NCT01506986
How many people
30024
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
The incidence of gastric cancer between the intervention and placebo groups
✗ The study did not show it
Who was studied
NCT02112214
How many people
5224
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Financial impact on the total cost of patient care resulting from implementation of a Pharmacogenetics testing program within a safety-net and Academic healthcare system
✗ The study did not show it
Who was studied
NCT02297126
How many people
4465
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.
✗ The study did not show it
Who was studied
NCT00251719
How many people
2054
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Percentage of Subjects With Complete Healing of Erosive Esophagitis (EE) by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.
✗ The study did not show it
Who was studied
NCT00251693
How many people
2038
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
pH of gastric contents
✗ The study did not show it
Who was studied
NCT02703896
How many people
1920
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Dexlansoprazole delayed-release capsules are a proton pump inhibitor (PPI) indicated in patients 12 years of age and older for: • Healing of all grades of erosive esophagitis (EE). ( 1.1 ) • Maintenance of healed EE and relief of heartburn. ( 1.2 ) • Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD).
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The safety and effectiveness of dexlansoprazole have not been established in pediatric patients less than 12 years of age.”
US prescribing information · caad4ada-2cf9-4e12-99df-6ca4388cf0f6 · read 2026-08-30
On older people, the label states: “Of the total number of patients (n=4,548) in clinical studies of dexlansoprazole, 11% of patients were aged 65 years and over, while 2% were 75 years and over.”
US prescribing information · caad4ada-2cf9-4e12-99df-6ca4388cf0f6 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary There are no studies with dexlansoprazole use in pregnant women to inform a drug-associated risk.”
US prescribing information · caad4ada-2cf9-4e12-99df-6ca4388cf0f6 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There is no information regarding the presence of dexlansoprazole in human milk, the effects on the breastfed infant, or the effects on milk production.”
US prescribing information · caad4ada-2cf9-4e12-99df-6ca4388cf0f6 · read 2026-08-30
On people with reduced liver function, the label states: “No dosage adjustment for dexlansoprazole delayed-release capsules is necessary for patients with mild hepatic impairment (Child-Pugh Class A).”
US prescribing information · caad4ada-2cf9-4e12-99df-6ca4388cf0f6 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
A different form was studied
The studied form is not the form on the shelf.
On this record: This record is linked to 1 related forms. Evidence does not carry across all of them.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
RNAWiki has not recorded a supervision or regulatory status for this substance.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
No register row and no identity class settled the question.
No source is stored against this line.
What is in the pack
Sold as capsule, delayed release, tablet, orally disintegrating, delayed release, given by the oral route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
41 products list this as an active ingredient in the United States drug directory. 41 of them contain it and nothing else.
FDA National Drug Code directory · 64374-101 · read 2026-08-29
They are sold as capsule, delayed release, capsule, delayed release pellets and powder, taken oral.
FDA National Drug Code directory · 64374-101 · read 2026-08-29
The regulator's established pharmacologic class for it is proton pump inhibitor [epc] and proton pump inhibitors [moa].
FDA National Drug Code directory · 64374-101 · read 2026-08-29
15 published labels name it as an active ingredient. 15 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · caad4ada-2cf9-4e12-99df-6ca4388cf0f6 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · caad4ada-2cf9-4e12-99df-6ca4388cf0f6 · read 2026-08-29
Dexlansoprazole is oral at 3 DOSAGE FORMS AND STRENGTHS Dexlansoprazole Delayed-Release Capsules 30 mg: strength is an opaque, white capsule with “par” imprinted on the cap and “147” imprinted on the body. 60 mg: strength is an opaque, green caps…, recorded as fda label in effect 2024-01-29 in the United States.
US prescribing information · caad4ada-2cf9-4e12-99df-6ca4388cf0f6 · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
This order is fixed in code and does not count clicks or time on the page.
What is not here
9 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
How close this is to real life — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
Felt, measured, or meaningful — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (10)
Q1
On the Dexlansoprazole label: indicated for what?
"Dexlansoprazole delayed-release capsules are proton pump inhibitor (PPI) indicated in patients 12 years of age and older for: Healing of all grades of erosive esophagitis (EE). ( 1.1 ) Maintenance of healed EE and relief of heartburn.": indications and usage on Dexlansoprazole's label. DailyMed label · 59e0c5d7-12e9-b5d7-e063-6394a90a7366 · 2026-08-25
Q2
47 registered trials of Dexlansoprazole — at which phases?
safety (1), accrual/recruitment (1), funding/business (1), sponsor decision unspecified (1) and other (4): Dexlansoprazole's stop wording, clustered. CLINICALTRIALS_SNAPSHOT · 2026-09-01
"Principal investigator left institution"; 8 of 47 registered studies
Show the evidence
Trial
NCT01317472
terminated; "Principal investigator left institution"
NCT01328392
withdrawn; "The sponsor did not fund the study."
NCT01479231
withdrawn; "Souces of funding have been terminated"
NCT01637571
withdrawn; "Sponsor could not fund"
NCT02162758
terminated; "Business Decisions; No Safety Concerns"
NCT02442752
withdrawn; "Withdrawn: Business decision (no enrollment)"
2 further recorded trials
NCT02615184
terminated; "Study related"
NCT02873702
terminated; "Compound is not expected to change the current treatment practice or fill significant clinical need for patients in China over currently available EE agents."
recorded 2026-09-01 · last checked 2026-09-04
Q4
Human studies of Dexlansoprazole used Dexlansoprazole 60 MG — over how long?
Human studies of Dexlansoprazole used "Dexlansoprazole 60 MG". ClinicalTrials.gov · 2026-09-01
5 recorded entries; human; capsule; also "Dexilant 60 MG", "Dexlansoprazole 60 mg once daily", "Dexilant® 60 mg capsule, hard"
Show the evidence
human
NCT03043521
Dexlansoprazole 60 MG
NCT03079050
Dexilant 60 MG
NCT03087162
Dexlansoprazole 60 mg once daily
NCT04877834
capsule; Dexilant® 60 mg capsule, hard
NCT06778395
Dexlansoprazole 60 mg
recorded 2026-09-01 · last checked 2026-09-04
Q5
Dexlansoprazole's half-life is 7 Days — which schedules were studied?
7 Days, the half-life Dexlansoprazole's label states: "Mean (%CV) Pharmacokinetic Parameters in Patients 12 to 17 Years of Age with Symptomatic GERD on Day 7 After Administration of Dexlansoprazole Delayed-Release Capsules Once Daily for 7 Days Dose C max (ng/mL) AUC tau (ng∙h/mL) CL/F (L/h) 30 mg (N=17) 691 (53) 2886 (47) 12.8 (48) 60 mg (N=18) 1136 (51) 5120 (58) 15.3…" DailyMed label · 59e0c5d7-12e9-b5d7-e063-6394a90a7366 · 2026-08-25
tmax 0.7 hours.
Show the evidence
half lifepharmacokinetics
7 Days; Mean (%CV) Pharmacokinetic Parameters in Patients 12 to 17 Years of Age with Symptomatic GERD on Day 7 After Administration of Dexlansoprazole Delayed-Release Capsules Once Daily for 7 Days Dose C max (ng/mL) AUC tau (ng∙h/mL) CL/F (L/h) 30 mg (N=17) 691 (53) 2886 (47) 12.8 (48) 60 mg (N=18) 1136 (51) 5120 (58) 15.3 (49) Age: Geriatric Population The terminal elimination half-life of…
tmaxpharmacokinetics
0.7 hours; Effect on Food In food-effect studies in healthy subjects receiving dexlansoprazole delayed-release capsules under various fed conditions compared to fasting, increases in C max ranged from 12 to 55%, increases in AUC ranged from 9 to 37%, and T max varied (ranging from a decrease of 0.7 hours to an increase of three hours) [see Dosage and Administration (2.3) ] .
metabolismpharmacokinetics
Metabolism Dexlansoprazole is extensively metabolized in the liver by oxidation, reduction, and subsequent formation of sulfate, glucuronide and glutathione conjugates to inactive metabolites.
recorded 2026-08-25 · last checked 2026-09-04
Q6
Which 10 trials of Dexlansoprazole posted no result?
Posted no result
10 of 10 completed trials
Registrations
NCT01149395, NCT02529787, NCT03043521, NCT03128736, NCT03011125 and NCT03079050, and 4 more
Completion dates
oldest 2012-04; newest 2022-11-25
Show the evidence
Trial
NCT01149395
2012-04
NCT02529787
2013-03
NCT03043521
2015-08-12
NCT03128736
2016-03-30
NCT03011125
2017-03-09
NCT03079050
2017-07-30
4 further recorded trials
NCT03319121
2017-12
NCT03087162
2017-12-01
NCT03202537
2022-07-31
NCT04877834
2022-11-25
Q7
At the median, Dexlansoprazole's trials enrolled 68 people — anything larger?
Median enrolment
68
Largest enrolment
2054
Registered trials counted
47
Q8
What do 3562 spontaneous reports say about Dexlansoprazole — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Dexlansoprazole appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 3562 reaction mentions were counted: chronic kidney disease 1349; acute kidney injury 632; renal failure 449; renal injury 333. FAERS via Open Targets · CHEMBL1201863 · 2026-06-24
Show the evidence
chronic kidney disease
1349
acute kidney injury
632
renal failure
449
renal injury
333
end stage renal disease
318
tubulointerstitial nephritis
139
4 more recorded rows
gastrooesophageal reflux disease
114
renal impairment
101
rebound acid hypersecretion
75
renal haemangioma
52
recorded 2026-06-24 · last checked 2026-09-04
Q9
Which 10 reactions does Dexlansoprazole's label not list?
Clinically Relevant Interactions Affecting Dexlansoprazole Delayed-Release Capsules When Co-Administered with Other Drugs and Substances CYP2C19 or CYP3A4 Inducers Clinical Impact: Decreased exposure of dexlansoprazole when used concomitantly with strong inducers [see Clinical Pharmacology (12.3) ] .
drug_interactions
CYP2C19 or CYP3A4 Inhibitors Clinical Impact: Increased exposure of dexlansoprazole is expected when used concomitantly with strong inhibitors [see Clinical Pharmacology (12.3) ] .
pharmacokinetics
Oxidative metabolites are formed by the cytochrome P450 (CYP) enzyme system including hydroxylation mainly by CYP2C19, and oxidation to the sulfone by CYP3A4.
pharmacokinetics
Elimination Effect of Dexlansoprazole on Other Drugs Cytochrome P 450 Interactions Dexlansoprazole is metabolized, in part, by CYP2C19 and CYP3A4 [see Clinical Pharmacology (12.3) ] .
pharmacokinetics
Furthermore, in vivo studies showed that dexlansoprazole delayed-release capsules did not have an impact on the pharmacokinetics of co-administered phenytoin (CYP2C9 substrate) or theophylline (CYP1A2 substrate).
pharmacokinetics
The subjects' CYP1A2 genotypes in the drug-drug interaction study with theophylline were not determined.
2 more recorded rows
Interaction statementpharmacokinetics
Effect of Other Drugs on Dexlansoprazole Because dexlansoprazole is metabolized by CYP2C19 and CYP3A4, inducers and inhibitors of these enzymes may potentially alter exposure of dexlansoprazole.
Interaction statementclinical_pharmacology
Oxidative metabolites are formed by the cytochrome P450 (CYP) enzyme system including hydroxylation mainly by CYP2C19, and oxidation to the sulfone by CYP3A4.
ChEMBL 37 — CC BY-SA 3.0 Unported · ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 6 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.